logo
California LGBTQ+ youth lose suicide hotline support

California LGBTQ+ youth lose suicide hotline support

Axios26-06-2025
The Trump administration is removing suicide counselors for LGBTQ+ youth from the 988 crisis hotline.
Why it matters: Those kids already face barriers to mental health care in California.
President Trump is targeting a group that is more than four times as likely than its peers to attempt suicide.
Driving the news: Starting July 17, callers will no longer be connected to the Trevor Project 's specialized hotline, because the service ran out of congressionally directed funding, according to the Department of Health and Human Services.
The hotline's general services will remain available.
What they're saying: "This is devastating, and we fear there will be compounding consequences. It is intentionally cruel for this to happen during Pride month," said Lance Toma, CEO of the San Francisco Community Health Center.
Zoom in: The San Francisco metro area is home to the highest concentration of LGBTQ+ people in the U.S., per 2021 Williams Institute estimates.
Stunning stat: 35% of LGBTQ+ young people in California, including 39% of transgender and nonbinary youth, seriously considered suicide in the past year, according to a 2024 survey by The Trevor Project.
Both figures are slightly lower than the nationwide statistics.
Between the lines: As some providers scale back services for LGBTQ+ youth, Toma told Axios that his organization will continue to provide gender-affirming medical care, case management and mental health services through their drop-in clinic TransThrive, and housing support via the Taimon Booton Navigation Center.
"Right now, LGBTQ+ youth need to know they are not alone. They belong. And we are fighting for them," Toma said.
State of play: California lands near the middle of the pack when it comes to using 988, which launched in 2022 to help address America's mental health crisis.
By the numbers: California saw a rate of 25.5 contacts per 1,000 people last year, making it the 21st-highest in the nation, per new research published in JAMA Network Open.
The national average was 23.7.
Alaska (45.3) and Vermont (40.2) had the highest 988 contact rates among states in 2024, while Delaware (12.5) and Alabama (14.4) had the lowest.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citi Remains Bullish on Sana Biotechnology (SANA)
Citi Remains Bullish on Sana Biotechnology (SANA)

Yahoo

time17 minutes ago

  • Yahoo

Citi Remains Bullish on Sana Biotechnology (SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10

Yahoo

time17 minutes ago

  • Yahoo

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10

Atai Life Sciences (NASDAQ:ATAI) is one of the best biotech penny stocks to buy right now. On July 30, H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Atai Life Sciences (NASDAQ:ATAI) to $15 from $10 while keeping a Buy rating on the shares. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The firm told investors that it is bullish on Atai Life Sciences (NASDAQ:ATAI) despite the Phase 2b trial, which evaluated indiabine in patients with cognitive impairment associated with schizophrenia, missing the primary endpoint. The analyst added in a research note that management reiterated Atai Life Sciences' (NASDAQ:ATAI) focus on its wholly-owned psychedelics pipeline in a follow-up call. This includes BPL-003, which has continued to surpass expectations. The firm thus cited Atai Life Sciences' (NASDAQ:ATAI) focus on its 'most promising near-term asset' for the target upgrade. Headquartered in Germany, Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on treating mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy
Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy

Yahoo

time22 minutes ago

  • Yahoo

Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) is one of the stocks under $10 to buy now. On July 29, AscellaHealth announced its successful HUB partnership with Abeona Therapeutics in the pre- and post-launch commercialization of ZEVASKYN (prademagene zamikeracel), which is an FDA-approved cell-based gene therapy. The collaboration addresses the clinical, operational, and reimbursement needs of this novel autologous cell-based gene therapy by designing and executing patient-centric, end-to-end solutions. An outcome of this partnership was the development and launch of AbeonaAssist, which is a customized patient support program designed to provide a seamless experience for patients, caregivers, and healthcare providers. A close-up of a staff member counting pills in a pharmaceutical warehouse. ZEVASKYN is the first and only autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa/RDEB. Abeona Therapeutics Inc. (NASDAQ:ABEO) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening diseases. While we acknowledge the potential of ABEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store